Ocugen licenses OCU400 to Celairis for Australia, New Zealand and ASEAN markets
OCGN•Ocugen granted Celairis exclusive commercialization rights to OCU400 in Australia, New Zealand and ASEAN markets, with fees and potential milestones totaling up to $7.1 million. The deal also includes a high single-digit royalty on net sales and 50% of regional gross profits.
1. License terms
Ocugen granted Celairis exclusive commercialization rights to its investigational retinitis pigmentosa gene therapy OCU400 in Australia, New Zealand and ASEAN markets. License fees and potential milestones total up to $7.1 million, including $6.1 million tied to an upfront payment and top-line results; the deal also provides a high single-digit royalty on net sales and 50% of regional gross profits.
2. Development plans
Celairis will handle regional regulatory submissions, market access and commercialization. A planned supply agreement would cover manufacturing by Ocugen, and Phase 3 top-line results are expected in the first quarter of 2027, with regional submissions expected following planned global filings.
